๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer

โœ Scribed by Anne L. Thomas; Ken O'Byrne; Lynn Furber; Katie Jeffery; William P. Steward

Publisher
Springer
Year
2001
Tongue
English
Weight
62 KB
Volume
48
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of a modified combination
Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer
โœ Iรงli, Fikri; Karaoguz, Handan; Akbulut, Hakan; Dinรงol, Dilek; Demirkazik, Ahmet; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 52 KB ๐Ÿ‘ 2 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
โœ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 71 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEGโ€LD) and gemcitabine have singleโ€agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie